So, this immateriality graphic here again appears. Soon enough, Merck will be trading back above $110 per share -- you heard it here first. Here's the latest from the Q3 2024 results disclosures:
. . .Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations as the company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.
But Merck’s vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., posted another quarter of lighter-than-expected sales. Revenue from the shot, Gardasil, fell 11% compared to the year-earlier period, mainly due to lower demand in China.
The pharmaceutical giant narrowed its full-year sales forecast to a range of $63.6 billion to $64.1 billion, from a previous guidance of $63.4 billion to $64.4 billion. . . .
Merck also lowered its adjusted profit guidance from a range of $7.72 to $7.77 per share, from a previous forecast of $7.94 to $8.04 per share. That updated outlook reflects a one-time charge of 24 cents per share related to business development deals with Curon Biopharmaceutical and Daiichi Sankyo. . . .
And, speaking of vaccines -- I hate to even mention it, but we must keep truth at the forefront. It seems some loons are claiming that Mpox Clade 1b infections are a "side effect" of the Pfizer COVID vaccine. This is insane, and has been debunked now by dozens of reputable researchers, including CIDRAP.
Onward -- to enjoy unusually warm and sunny outdoor trick or treating parties with the grand nieces / munchkins!
नमस्ते
No comments:
Post a Comment